Granules India has received the inspection report from INFARMED (InstitutoNacional da Farmacia E Do Medicamento), Portugal with 11 observations. The Gagillapur facility manufactures Pharmaceutical Formulation Intermediates (PFIs) and Finished Dosages (FDs). INFARMED Portugal had conducted a renewal inspection on the company’s facility located at Gagillapur, Telangana, India.
The company has initiated necessary steps to address the observations of the inspection agency and will submit its response with a corrective and preventive action plan within stipulated time. The company will also be requesting the INFARMED for re-inspection of the Gagillapur facility at the earliest.
Granules India is a pharmaceutical company with presence across the pharmaceutical manufacturing value chain, including active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediaries (PFIs) and finished dosages (FDs).
| Company Name | CMP |
|---|---|
| Sun Pharma. Inds. | 1904.65 |
| Dr. Reddys Labs. | 1374.55 |
| Cipla | 1458.45 |
| Zydus Lifesciences | 1141.00 |
| Lupin | 2476.10 |
| View more.. | |
Start Research-backed Investing ...Now. Subscribe to Sapphire
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: